{
    "clinical_study": {
        "@rank": "36983", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: CP-B: MK-5172 50 mg/MK-8742 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172, two 25-mg tablets, orally, once per day (QD) + MK-8742 50 mg tablet, orally, QD for 12 weeks"
            }, 
            {
                "arm_group_label": "Arm 2: Non-cirrhotics: MK-5172 100 mg/MK-8742 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172 100 mg tablet, orally, QD + MK-8742 50 mg tablet, orally, QD for 12 weeks"
            }, 
            {
                "arm_group_label": "Arm 3: CP-B: MK-5172 100 mg/MK-8742 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172 100 mg tablet, orally, QD + MK-8742 50 mg tablet, orally, QD for 12 weeks (CP-B subjects)"
            }, 
            {
                "arm_group_label": "Arm 4: CP-B: MK-5172 50mg or 100 mg/MK-8742 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172, two 25-mg tablets, orally, QD + MK-8742 50 mg tablet, orally, QD for 12 weeks OR MK-5172 100 mg tablet, orally, QD + MK-8742 50 mg tablet, orally, QD for 12 weeks, depending on results in Arm 1"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done to evaluate the efficacy and safety of the drug combination MK-5172\n      + MK-8742 in participants with chronic hepatitis C (CHC) genotype (GT) 1, 4-6 infection and\n      who have cirrhosis and Child-Pugh (CP) score 7-9 moderate hepatic insufficiency. The primary\n      hypothesis is that the percentage of HCV-infected participants with hepatic insufficiency\n      (the CP-B population) achieving sustained viral response (SVR) 12 weeks after the end of all\n      treatment (SVR12) will be greater than 60%. Additionally, ten non-cirrhotic HCV-infected GT1\n      participants will also be given MK-5172 + MK-8742 at the beginning of the study; this will\n      be done for the purpose of collecting plasma pharmacokinetic data in HCV GT1-infected\n      participants who do not have hepatic insufficiency."
        }, 
        "brief_title": "Study of Efficacy and Safety of MK-5172 + MK-8742 in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic", 
                "Hepatic Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be conducted sequentially in 3 Parts.  Each participant will participate in\n      only one Part.\n\n      Participants will be enrolled in either Part A, Part B, or Part C:\n\n        -  Part A: CP-B participants will receive MK-5172 50 mg/ MK-8742 50 mg; non-cirrhotic\n           participants will receive MK-5172 100 mg/MK-8742 50 mg.\n\n        -  Part B: CP-B participants will receive MK-5172 100 mg/MK-8742 50 mg.\n\n        -  Part C: CP-B participants will receive either MK-5172 50 mg or 100 mg/MK-8742 50 mg.\n\n      Study progression from Part A to Part B and from Part B to Part C will be based upon a\n      review of safety and efficacy in Parts A and B, respectively.  Depending upon safety and\n      efficacy in Part A, the study may progress directly from Part A to Part C using MK-5172 50\n      mg/MK-8742 50 mg, without performing Part B."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Documented chronic HCV GT1 infection (for Arm 4 participants may have GT4, GT5, or\n             GT6 infection) with no evidence of non-typable or mixed genotype) infection\n\n          -  Evidence of hepatic cirrhosis with a score on the Child-Pugh scale from 7 to 9 and\n             not anticipated to receive a liver transplant within the next 36 weeks (for Arm 1,\n             Arm 3, and Arm 4)\n\n          -  No evidence of cirrhosis (only for Arm 2 )\n\n          -  Participants of reproductive potential must agree to remain truly abstinent or use\n             (or have their partner use) 2 acceptable methods of birth control from at least 2\n             weeks prior to Day 1 and continue until at least 6 months after last dose of study\n             drug, or longer if dictated by local regulations\n\n        Exclusion criteria:\n\n          -  Co-infected with hepatitis B virus or human immunodeficiency virus (HIV)\n\n          -  Previously received direct-acting antiviral therapy for HCV\n\n          -  History of malignancy <=5 years prior to signing informed consent except for\n             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n             or carcinoma in situ; or under evaluation for other active or suspected malignancy\n\n             _ Cirrhosis and liver imaging within 4 weeks prior to screening showing evidence of\n             hepatocellular carcinoma (HCC), or is under evaluation for HCC\n\n          -  Currently participating or has participated in a study with an investigational\n             compound within 30 days of signing informed consent and is not willing to refrain\n             from participating in another such study during the course of this study\n\n          -  Clinically-relevant drug or alcohol abuse within 12 months of screening\n\n          -  Pregnant or breast-feeding, or expecting to conceive or donate eggs or sperm from at\n             least 2 weeks prior to Day 1 and continue throughout treatment and follow up, or\n             longer if dictated by local regulations\n\n          -  Organ transplants (including hematopoietic stem cell transplants) other than cornea\n             and hair\n\n          -  Poor venous access\n\n          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption\n             disorders (e.g., celiac sprue disease)\n\n          -  Requiring, or likely to require, chronic systemic administration of corticosteroids\n             during the course of the trial\n\n          -  Evidence or history of chronic hepatitis not caused by HCV, including but not limited\n             to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune\n             hepatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115321", 
            "org_study_id": "5172-059", 
            "secondary_id": "2014-000672-25"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: CP-B: MK-5172 50 mg/MK-8742 50 mg", 
                    "Arm 2: Non-cirrhotics: MK-5172 100 mg/MK-8742 50 mg", 
                    "Arm 3: CP-B: MK-5172 100 mg/MK-8742 50 mg", 
                    "Arm 4: CP-B: MK-5172 50mg or 100 mg/MK-8742 50 mg"
                ], 
                "intervention_name": "MK-5172", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1: CP-B: MK-5172 50 mg/MK-8742 50 mg", 
                    "Arm 2: Non-cirrhotics: MK-5172 100 mg/MK-8742 50 mg", 
                    "Arm 3: CP-B: MK-5172 100 mg/MK-8742 50 mg", 
                    "Arm 4: CP-B: MK-5172 50mg or 100 mg/MK-8742 50 mg"
                ], 
                "intervention_name": "MK-8742", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Murray", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84107"
                }, 
                "name": "Call for Information (Investigational Site 0002)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection With Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants achieving SVR12", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Number of participants experiencing adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 weeks"
            }, 
            {
                "measure": "Number of participants discontinuing study drug due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change from Baseline in the model for the end-stage liver disease (MELD) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Number of participants achieving undetectable or below limit of quantification levels of HCV ribonucleic acid (RNA) by Week 2", 
                "safety_issue": "No", 
                "time_frame": "Week 2 of treatment"
            }, 
            {
                "measure": "Number of participants achieving undetectable or below limit of quantification levels of HCV RNA by Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4 of treatment"
            }, 
            {
                "measure": "Number of participants achieving undetectable or below limit of quantification levels of HCV RNA by Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12 of treatment"
            }, 
            {
                "measure": "Number of participants achieving SVR at 4 weeks after the end of all treatment (SVR4)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "Number of participants achieving SVR at 24 weeks after the end of all treatment (SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 36"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}